Internal Medicine, Medical Oncology · Springfield, MA
NPI
1326066200
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
3350 Main St
Springfield, MA, 01107
Phone (413) 794-9338
Groups this clinician bills Medicare through
Medicare paid, 2024
$55K
771 services
Medicare patients, 2024
273
Average age 73
Drug cost, 2024
$2.4M
422 prescriptions
Company payments, 2025
$4,414
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Armen Asik was code 99214 (office e&m - established), 506 times for 217 patients. In total Armen Asik billed 771 services in 10 codes, and Medicare paid $55K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 506 | 217 | $68.38 | $35K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 92 | 59 | $12.75 | $1,173 |
| 99215 Office E&M - Established | Facility | 85 | 52 | $109.16 | $9,279 |
| 99205 Office E&M - New | Facility | 34 | 34 | $134.59 | $4,576 |
| 99223 Hospital E&M - Initial | Facility | 26 | 26 | $135.90 | $3,533 |
By year: 2022 $68K for 773 services; 2023 $57K for 691 services; 2024 $55K for 771 services.
Medicare prescription drug claims, 2024
In 2024, the drug Armen Asik prescribed most often to Medicare patients was Imatinib Mesylate, with 58 prescriptions and refills. In total Armen Asik wrote 422 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imatinib Mesylate Generic | 58 | 58 | Under 11 | $166K |
| Gabapentin Generic | 23 | 23 | Under 11 | $319 |
| Eliquis Apixaban | 19 | 21 | Under 11 | $12K |
| Mirtazapine Generic | 18 | 26 | Under 11 | $401 |
| Pomalyst Pomalidomide | 16 | 16 | Under 11 | $367K |
| Lonsurf Trifluridine/Tipiracil Hcl | 15 | 15 | Under 11 | $143K |
| Oxycodone Hcl Generic | 14 | 14 | Under 11 | $148 |
| Lenvima Lenvatinib Mesylate | 13 | 13 | Under 11 | $313K |
| Abiraterone Acetate Generic | 12 | 12 | Under 11 | $52K |
| Creon Lipase/Protease/Amylase | 12 | 14 | Under 11 | $12K |
| Sorafenib Sorafenib Tosylate | 11 | 11 | Under 11 | $104K |
| Ninlaro Ixazomib Citrate | 11 | 11 | Under 11 | $147K |
| Votrient Pazopanib Hcl | 11 | 11 | Under 11 | $143K |
Brand drugs: 164 claims; generic drugs: 258 claims; opioid claims: 22.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Armen Asik $4,414 ($4,414 in general payments such as food, travel and fees) from 3 companies. The largest payer was Deciphera Pharmaceuticals Inc. with $2,647.
| Company | Payments | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 6 | $2,647 |
| BeOne Medicines USA, Inc. ONC | 1 | $1,650 |
| Adc Therapeutics America, Inc. | 1 | $117 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.